WZ811 (WZ-811; WZ 811) is a highly potent, selective, competitive antagonist of CXCR4 chemokine receptor with potential anticancer activity.

SRT3109 (SRT-3109) is a novel and potent antagonist of CXCR2 (C-X-C chemokine receptor type 2) with potential anti-Inflammatory and immunomodulatory activity.

Plerixafor (formerly known as SDZ-SID-791; JLK-169; SID-791; AMD3100, AMD-3100, JM-3100, JM 3100; trade name Mozobil), the so called ‘hematopoeitic stem cell mobilizer’, is a novel and potent chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with an IC50 of 44 nM and 5.7 nM in cell-free assays, respectively.

CXCR2-IN-1 is a novel CNS (central nervous system) penetrant antagonist of CXCR2 with a pIC50 of 9.3.

ATI-2341 (ATI2341), a pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is a novel and selective allosteric agonist of CXCR4 with anti-inflammatory and anticancer activity.

NBI-74330 (NBI74330) is a novel, potent and selective antagonist for CXCR3 (CXC chemokine receptor 3) with potential anticancer, immunomodulatory and antiinflammatory activities.

AZD8797 (AZD-8797) is a novel, selective, orally bioavailable and allosteric non-competitive modulator of the human CX3CR1 receptor with potential anti-Inflammatory and immunomodulatory activity.

AZD-5069 (AZD5069) is a novel and potent CXCR2 chemokine receptor antagonist with potential anticancer and antiinflammatory activities.

USL311 is a novel, selective and potent CXCR4 receptor antagonist with anticancer activity by disrupting the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4, which prevents CXCR4 activation and decreases proliferation and migration of CXCR4-expressing tumor cells.

IT1t is a novel, potent and selective CXCR4 antagonist with an IC50 of 1.1 nM in calcium mobilization assay, it can be potentially used as an anti-HIV agent.